{"meta":{"query_hash":"f45526ca5810","filters":{"venue":"ESMO rare cancers."},"cohort_total":18,"direct_labels_cover":0,"predictions_cover":18,"exported":18,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f45526ca5810","api":"https://metacan.xera.ac/api/v1/cohort?venue=ESMO+rare+cancers."},"results":[{"id":"W4417530834","doi":"10.1016/j.esmorc.2025.100073","title":"RADIOLOGIC RESPONSES IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Dermatological and Skeletal Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Feature (linguistics); Medical imaging; Disease; MEDLINE; Computed tomography","score_opus":0.006966873779264059,"score_gpt":0.2581287047792288,"score_spread":0.2511618309999647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94364005,0.01309677,0.0002781062,0.001969217,0.0003735991,0.00025163402,0.000039453244,0.000035325884,0.040315814],"genre_scores_gemma":[0.9876196,0.00099423,0.00017498495,0.0027033186,0.00004792607,0.000076114906,0.000057015204,0.000010301991,0.008316501],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988723,0.00011753079,0.00022188353,0.0004198222,0.00007212389,0.0002963802],"domain_scores_gemma":[0.9995129,0.000038235346,0.000044447195,0.0003243006,0.00003294718,0.000047146117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013826671,0.00016563926,0.00021732069,0.00011806261,0.00006251337,0.000016024853,0.00025411547,0.00017384859,0.00007702679],"category_scores_gemma":[0.00023295287,0.00013950902,0.00011734409,0.0002987871,0.00015303053,0.000003899866,0.00009703327,0.00011432123,0.000021996511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004850769,0.0005044984,0.15466146,0.0003522518,0.0004924002,0.00075831806,0.000349157,0.00055232603,0.39612326,0.011672356,0.2788701,0.15081309],"study_design_scores_gemma":[0.0033158083,0.00042497905,0.05884376,0.000107400265,0.000030806477,0.00007205298,0.000348178,0.000055854598,0.1430511,0.017393509,0.7755738,0.00078275445],"about_ca_topic_score_codex":0.000056227367,"about_ca_topic_score_gemma":0.00016235892,"teacher_disagreement_score":0.49670368,"about_ca_system_score_codex":0.000049007547,"about_ca_system_score_gemma":0.00013509385,"threshold_uncertainty_score":0.5689013},"labels":[],"label_agreement":null},{"id":"W4417530841","doi":"10.1016/j.esmorc.2025.100102","title":"NRG-DT001 PHASE IB TRIAL OF NEOADJUVANT NAVTEMADLIN AND RADIOTHERAPY IN TP53 WILD-TYPE SOFT TISSUE SARCOMA: PRELIMINARY EFFICACY ANALYSIS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Soft tissue sarcoma; Radiation therapy; Tolerability; Soft tissue; Sarcoma; Clinical trial; Phases of clinical research","score_opus":0.01758124853013332,"score_gpt":0.3460718606338129,"score_spread":0.3284906121036796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95645803,0.039470907,0.00012571678,0.001909669,0.00032786376,0.0012279031,0.000029367122,0.000040779687,0.0004097882],"genre_scores_gemma":[0.9950492,0.003170456,0.0006113251,0.00045432226,0.0001400716,0.000111697125,0.0000893758,0.000022994333,0.00035057258],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983391,0.00010162206,0.0005389358,0.00048071975,0.0002505421,0.0002890602],"domain_scores_gemma":[0.99880475,0.0003357834,0.00015264672,0.0004945326,0.000086930035,0.0001253693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020983382,0.00026004636,0.0010064908,0.0005351044,0.000055359742,0.000016015956,0.00011391474,0.00014685729,0.00021410311],"category_scores_gemma":[0.000099824625,0.00022110317,0.00019970995,0.0012713079,0.000120122495,0.00007463141,0.000038835642,0.00018004609,0.0000023793516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12409375,0.007851469,0.15457794,0.00040580163,0.006368833,0.0014209042,0.0022493275,0.0008797604,0.0010650604,0.00028298426,0.008774274,0.6920299],"study_design_scores_gemma":[0.5569036,0.011909376,0.36178795,0.0016774657,0.008183632,0.00005245706,0.0006726491,0.004397047,0.01438113,0.00029626323,0.03890818,0.0008302332],"about_ca_topic_score_codex":0.0013341386,"about_ca_topic_score_gemma":0.00020082844,"teacher_disagreement_score":0.69119966,"about_ca_system_score_codex":0.0004042135,"about_ca_system_score_gemma":0.0003566481,"threshold_uncertainty_score":0.90163255},"labels":[],"label_agreement":null},{"id":"W4417530842","doi":"10.1016/j.esmorc.2025.100077","title":"MANAGEMENT OF THE DUODENUM DURING RESECTION OF PRIMARY RETROPERITONEAL SARCOMA: SURGICAL AND ONCOLOGICAL OUTCOMES FROM A MULTICENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Duodenum; Multicenter study; Resection; Surgical resection; Segmental resection","score_opus":0.020621312955444945,"score_gpt":0.296546458373951,"score_spread":0.27592514541850605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520963,0.0013726418,8.0670327e-7,0.00090658787,0.00019181408,0.00075966923,0.000013743465,0.000013375247,0.0015317122],"genre_scores_gemma":[0.9991133,0.00021185173,0.00011894324,0.00006931276,0.000027229209,0.00008841243,0.000004791319,0.0000062476897,0.0003598878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990935,0.00007747065,0.0002600579,0.00023098501,0.00022144911,0.00011655344],"domain_scores_gemma":[0.9994805,0.000094182644,0.00007668319,0.00027422849,0.000040570678,0.000033854907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076635224,0.00010895298,0.0003745972,0.000044613073,0.000060602506,0.0000056182134,0.00007585341,0.000050001257,0.00006282789],"category_scores_gemma":[0.000014116909,0.000064074375,0.00009828975,0.00013507076,0.00008741092,0.000024314324,0.0001751023,0.000111836016,5.682303e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009398152,0.0009277188,0.9937838,0.0001470075,0.0005780742,0.00024245652,0.00022864774,0.0000033918034,0.00009912661,0.000031469925,0.00010961917,0.0029089],"study_design_scores_gemma":[0.006997863,0.00022788688,0.98839575,0.00038221583,0.0002946507,0.000002571442,0.00093227933,0.000007053241,0.0023933875,0.000010308311,0.00030951478,0.00004654693],"about_ca_topic_score_codex":0.00088464614,"about_ca_topic_score_gemma":0.00008748012,"teacher_disagreement_score":0.0060580475,"about_ca_system_score_codex":0.00037717272,"about_ca_system_score_gemma":0.000040815245,"threshold_uncertainty_score":0.26128772},"labels":[],"label_agreement":null},{"id":"W4417530843","doi":"10.1016/j.esmorc.2025.100061","title":"JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TO DRIVE CIC-REARRANGED SARCOMAS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Barrie Urology Group","funders":"","keywords":"Sarcoma; Mutation; Cancer; Cell culture","score_opus":0.017030919063464094,"score_gpt":0.3220248881436876,"score_spread":0.3049939690802235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9232122,0.0014863176,0.0003112583,0.010209763,0.00031562327,0.0022706306,0.00033438829,0.00022518903,0.06163465],"genre_scores_gemma":[0.9810452,0.00015425045,0.0011199375,0.0020967037,0.00013602649,0.0003449961,0.00022226475,0.000037125617,0.014843523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982013,0.0000693301,0.0002097589,0.0005014595,0.00042608695,0.000592052],"domain_scores_gemma":[0.99857527,0.00012335123,0.000037963033,0.00053864636,0.00022915906,0.000495624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000099729354,0.00027017965,0.00041904856,0.00025803185,0.0002803946,0.000051197123,0.00016767521,0.000093568364,0.0011620341],"category_scores_gemma":[0.000148192,0.00019441922,0.00008989074,0.0005629986,0.00011927037,0.00008562741,0.00007386673,0.00029284114,0.00025317742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007611084,0.00079838565,0.6251092,0.00051309273,0.0024670379,0.004554381,0.004907195,0.00016199582,0.025936155,0.0010357823,0.18730007,0.13960561],"study_design_scores_gemma":[0.018925859,0.002567171,0.44860992,0.001769794,0.00027469516,0.000083708495,0.002785155,0.00034208078,0.10904993,0.000104575454,0.41471308,0.0007740361],"about_ca_topic_score_codex":0.0015966612,"about_ca_topic_score_gemma":0.0017906319,"teacher_disagreement_score":0.22741301,"about_ca_system_score_codex":0.0006551251,"about_ca_system_score_gemma":0.0011863591,"threshold_uncertainty_score":0.99975103},"labels":[],"label_agreement":null},{"id":"W4417530849","doi":"10.1016/j.esmorc.2025.100092","title":"INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA, A PUSH PLATFORM STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Anschutz Medical Campus, University of Colorado; Università degli Studi di Torino; Albert-Ludwigs-Universität Freiburg; Justus Liebig Universität Gießen; University of Texas MD Anderson Cancer Center; St. Jude Children's Research Hospital; Universitätsklinikum Hamburg-Eppendorf; School of Medicine, Duke University; Ohio State University; University of Pennsylvania; Children's Hospital of Philadelphia; Nationwide Children's Hospital; Massachusetts Institute of Technology","keywords":"Retrospective cohort study; Multicenter study; MEDLINE; Real world data","score_opus":0.02273181365827817,"score_gpt":0.30612275018123375,"score_spread":0.28339093652295555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904914,0.00025699032,0.000015422616,0.0003137346,0.00061270484,0.0016523213,0.000016688706,0.000043285454,0.00803972],"genre_scores_gemma":[0.9988617,0.0000304765,0.00017395828,0.00022435491,0.000095127536,0.00022165405,0.000012856945,0.000018983854,0.00036093558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985799,0.000028832112,0.00037276873,0.00040995775,0.00039568223,0.00021283404],"domain_scores_gemma":[0.9991487,0.00005033279,0.00013901595,0.00038423997,0.00020781266,0.00006985147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011594725,0.00020026046,0.0004263838,0.00021792683,0.00009920781,0.00002839195,0.00016062065,0.000051890172,0.0002604288],"category_scores_gemma":[0.00004602668,0.00017013679,0.00011172961,0.0002836484,0.00004575371,0.00010577651,0.00011749997,0.00018541017,0.00000958518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040405281,0.0068032146,0.98300135,0.000028683795,0.00069483137,0.00010831838,0.0035367415,0.000015429516,0.00016379694,0.00002746482,0.0009523704,0.0042637195],"study_design_scores_gemma":[0.013054442,0.0010653429,0.96784735,0.00027800567,0.0003030268,0.0000021911485,0.012822278,0.00008340429,0.0037824323,0.000019366846,0.00062400784,0.000118180695],"about_ca_topic_score_codex":0.0018553935,"about_ca_topic_score_gemma":0.00034608046,"teacher_disagreement_score":0.015154054,"about_ca_system_score_codex":0.0010599156,"about_ca_system_score_gemma":0.00014192896,"threshold_uncertainty_score":0.6937977},"labels":[],"label_agreement":null},{"id":"W4417530851","doi":"10.1016/j.esmorc.2025.100096","title":"DATA DRIVEN MODELLING OF SPATIAL HETEROGENEITY IN SOFT TISSUE SARCOMAS IDENTIFIES PROGNOSTIC GROUPS FOLLOWING NEOADJUVANT CHEMOTHERAPY: ANALYSIS OF THE ISG-STS-1001 TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Soft tissue; Radiation therapy; Neoadjuvant therapy; Data-driven; Tumour heterogeneity; Sarcoma; Spatial heterogeneity","score_opus":0.02480526418381184,"score_gpt":0.29160813987829093,"score_spread":0.2668028756944791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97492915,0.003139068,0.020252623,0.00014238991,0.00061006006,0.000486091,0.00036223012,0.0000048813313,0.000073524396],"genre_scores_gemma":[0.99851686,0.0005233011,0.00026594728,0.0001293903,0.00011798182,0.000021425572,0.00036331342,0.000015751688,0.000046021465],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986768,0.00006090113,0.00042677767,0.00045503338,0.00017066808,0.00020984479],"domain_scores_gemma":[0.9986752,0.00006501525,0.00020849127,0.0009509607,0.00006712234,0.00003317508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022801668,0.0001613283,0.00041513753,0.00010305425,0.00006380319,0.000022414768,0.00066794443,0.00013248819,0.00001890126],"category_scores_gemma":[0.0001402151,0.00014917634,0.00023222817,0.0003794076,0.00010123495,0.0000076285896,0.00038108163,0.00009773578,2.9544466e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067838933,0.0005491268,0.26070705,0.0003237032,0.006779862,0.00002247367,0.0011560452,0.58761203,0.10476064,0.00012282043,0.002564834,0.028617479],"study_design_scores_gemma":[0.046167742,0.00093243417,0.088989645,0.00080025865,0.005756571,0.000002838801,0.00075283385,0.3507789,0.48588648,0.00092494977,0.017470464,0.0015368635],"about_ca_topic_score_codex":0.0034754295,"about_ca_topic_score_gemma":0.018004213,"teacher_disagreement_score":0.38112584,"about_ca_system_score_codex":0.00006630907,"about_ca_system_score_gemma":0.00037962286,"threshold_uncertainty_score":0.99991465},"labels":[],"label_agreement":null},{"id":"W4417530860","doi":"10.1016/j.esmorc.2025.100076","title":"GENOME-WIDE SEQUENCING ANALYSES REVEAL THE BIOLOGICAL DETERMINANTS OF RESECTION MARGIN STATUS IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Liposarcoma; Resection margin; Resection; Margin (machine learning); Surgical margin; Radiation therapy","score_opus":0.05800347749770376,"score_gpt":0.33361318267646034,"score_spread":0.2756097051787566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992957,0.005145058,0.000008132997,0.0003536234,0.00018211754,0.00044421275,0.000024917925,0.00002780406,0.0008571084],"genre_scores_gemma":[0.9979092,0.0011579825,0.00016682013,0.00039328018,0.000056445133,0.0000979747,0.000072930285,0.000011342274,0.00013406412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985831,0.00015976549,0.0004184879,0.00031858744,0.00018752109,0.00033258388],"domain_scores_gemma":[0.9991977,0.00020321007,0.00012100187,0.0003263389,0.000085678825,0.000066049724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016729336,0.00017264351,0.00047841115,0.00020503774,0.000083845705,0.000013548912,0.00011186025,0.00011660135,0.000073475494],"category_scores_gemma":[0.00015836296,0.000106503394,0.00012363281,0.00056154974,0.000129219,0.000045651737,0.000075987635,0.0002243148,0.0000024369406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052915653,0.00010560856,0.98403436,0.00009470733,0.00013217483,0.00018604458,0.00016386315,0.00001805479,0.008656792,0.0000044587614,0.00021178012,0.0058630034],"study_design_scores_gemma":[0.0014033557,0.00024302042,0.971127,0.0003621972,0.00011349298,0.0000131084325,0.0003037725,0.000055918415,0.025969513,0.00003936673,0.00028164132,0.00008765436],"about_ca_topic_score_codex":0.0028795968,"about_ca_topic_score_gemma":0.0009773425,"teacher_disagreement_score":0.01731272,"about_ca_system_score_codex":0.001622576,"about_ca_system_score_gemma":0.0004746189,"threshold_uncertainty_score":0.4353108},"labels":[],"label_agreement":null},{"id":"W4417530862","doi":"10.1016/j.esmorc.2025.100084","title":"PREDICTING FAILURE OF ACTIVE SURVEILLANCE IN DESMOID-TYPE FIBROMATOSIS USING RADIOMICS: AN INTERNATIONAL MULTI-CENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Sinai Health System","funders":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Thomas Jefferson University; University of Miami","keywords":"Radiomics; Fibromatosis; Medical imaging; MEDLINE; Personalized medicine","score_opus":0.032320563403784405,"score_gpt":0.3448138099901654,"score_spread":0.312493246586381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980602,0.00019581639,0.000062830644,0.00018415402,0.0005626345,0.00058783777,0.000042523854,0.000057026977,0.00024697848],"genre_scores_gemma":[0.99820656,0.000031878717,0.0014042382,0.000095927906,0.00010180404,0.000024940568,0.000027570099,0.000021561165,0.00008553389],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877685,0.00008363263,0.00035240644,0.00036133148,0.00021449276,0.00021130737],"domain_scores_gemma":[0.9991884,0.00009940747,0.00013693291,0.00028703836,0.00023709514,0.00005108024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016691866,0.00017476741,0.0004390457,0.00026817946,0.00005885132,0.000011333657,0.00015041653,0.000060253908,0.000045963083],"category_scores_gemma":[0.00036415644,0.0001762295,0.000056195684,0.00046615858,0.00008764889,0.00017516312,0.00010174399,0.00020410567,0.0000013003962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049758167,0.0003387141,0.9927775,0.00008066436,0.00037021245,0.000076840595,0.0035834287,0.00020741641,0.0011374097,0.000005270239,0.000119417244,0.0008055265],"study_design_scores_gemma":[0.0070465063,0.00026677267,0.9720288,0.0006475388,0.0000680449,0.000026031079,0.011776907,0.0041911406,0.0034924785,0.0000047832227,0.00028944405,0.00016157328],"about_ca_topic_score_codex":0.0020965158,"about_ca_topic_score_gemma":0.002240652,"teacher_disagreement_score":0.020748738,"about_ca_system_score_codex":0.000785726,"about_ca_system_score_gemma":0.00026280925,"threshold_uncertainty_score":0.71864307},"labels":[],"label_agreement":null},{"id":"W4417530877","doi":"10.1016/j.esmorc.2025.100056","title":"INTEGRATED EFFICACY AND SAFETY ANALYSIS OF LETETRESGENE AUTOLEUCEL, A T-CELL RECEPTOR T-CELL THERAPY, ACROSS CLINICAL TRIALS OF PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Soft tissue sarcoma; Synovial sarcoma; Liposarcoma; Sarcoma; Receptor","score_opus":0.03792771047108455,"score_gpt":0.35563736217022296,"score_spread":0.3177096516991384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859402,0.011071245,0.000050628318,0.00021607435,0.00020695412,0.001181629,0.0009098681,0.000031741416,0.00039162146],"genre_scores_gemma":[0.9945206,0.0036750273,0.0007604071,0.0002449859,0.000048010148,0.000052359108,0.00043333857,0.000032797376,0.00023247914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652463,0.0005249637,0.0015212196,0.00069291104,0.00037844328,0.00035785182],"domain_scores_gemma":[0.99640644,0.0016818023,0.00075646915,0.00058124197,0.00035486248,0.00021916171],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001013006,0.0004007695,0.0021696738,0.00032931074,0.000113181064,0.000033896955,0.00015346082,0.00023848284,0.00020284629],"category_scores_gemma":[0.0002036903,0.0002777149,0.00040404082,0.0011336891,0.00041766212,0.00006947687,0.00009507673,0.00027770898,0.0000014585409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103955045,0.0044065965,0.8962274,0.00021687025,0.003920887,0.000022299246,0.0006630708,0.000021367207,0.0018755032,0.000008492405,0.0011224119,0.0811196],"study_design_scores_gemma":[0.042088624,0.0033180632,0.9133204,0.00032362147,0.0041582063,8.9830286e-7,0.00057390647,0.00015214494,0.027945213,0.000005331874,0.0077856285,0.00032792383],"about_ca_topic_score_codex":0.0009679789,"about_ca_topic_score_gemma":0.00018996539,"teacher_disagreement_score":0.080791675,"about_ca_system_score_codex":0.00021788967,"about_ca_system_score_gemma":0.00047932199,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null},{"id":"W4417530885","doi":"10.1016/j.esmorc.2025.100072","title":"OVERCOMING MTOR INHIBITOR RESISTANCE IN PECOMA: UPDATED RESULTS ON AROMATASE INHIBITOR ADDITION FROM A REFERRAL CENTER","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Discovery and development of mTOR inhibitors; Aromatase inhibitor; Aromatase; Clinical trial; PI3K/AKT/mTOR pathway; Referral","score_opus":0.01383670230329569,"score_gpt":0.2705782362036146,"score_spread":0.2567415339003189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729269,0.0005293359,0.000014030427,0.0030923113,0.0014411854,0.00066874747,0.0020420193,0.00016550293,0.01911997],"genre_scores_gemma":[0.9909638,0.000075050986,0.0004956438,0.0026629167,0.0008235622,0.00009161163,0.0023234726,0.00003342738,0.0025304828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810886,0.00011075049,0.0005072572,0.0005928442,0.00028868948,0.00039160033],"domain_scores_gemma":[0.99890435,0.00023201443,0.00013371806,0.00053459214,0.00006440882,0.00013089404],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018350966,0.00026703294,0.00044315108,0.00030563545,0.00008303682,0.000030127927,0.00011784597,0.00019597297,0.0002280789],"category_scores_gemma":[0.0003542239,0.00025134167,0.00010512249,0.0005148823,0.00005371582,0.00015928516,0.000050440725,0.0004740311,0.0000903307],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016607437,0.00035891953,0.005642962,0.00020825502,0.00011296239,0.00089474133,0.0005465399,0.00001361569,0.005922129,0.00020841969,0.96653205,0.0029519682],"study_design_scores_gemma":[0.051067386,0.00067548465,0.1264976,0.012026973,0.00021663995,0.00001302977,0.0006721549,0.00027305042,0.08327213,0.0011174974,0.7231701,0.0009979864],"about_ca_topic_score_codex":0.0007223439,"about_ca_topic_score_gemma":0.0014842328,"teacher_disagreement_score":0.24336198,"about_ca_system_score_codex":0.0011762162,"about_ca_system_score_gemma":0.00027471795,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W4417530891","doi":"10.1016/j.esmorc.2025.100116","title":"THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; European Network for Rare Adult Solid Cancers; Feinberg School of Medicine; Centre Léon Bérard; Universitair Medisch Centrum Groningen; Cleveland Clinic; University College London; Institut Gustave-Roussy; Vanderbilt University; Moffitt Cancer Center; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, San Francisco; Vanderbilt University Medical Center; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Johns Hopkins University; University of Texas MD Anderson Cancer Center; Northwestern University; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Agonist; Placebo; Clinical trial; Receptor; Phase (matter)","score_opus":0.023166413158263975,"score_gpt":0.3242507285497494,"score_spread":0.30108431539148545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9524387,0.007531484,0.000012788925,0.02654571,0.0013876371,0.004328724,0.00043340412,0.00007990389,0.007241606],"genre_scores_gemma":[0.98791575,0.0015341018,0.000076515935,0.0011095677,0.00028031017,0.0010252175,0.00040666416,0.000026281983,0.0076255663],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973602,0.00036911241,0.0007992305,0.0006178423,0.00047456785,0.00037904625],"domain_scores_gemma":[0.9968838,0.0017386182,0.00022881773,0.0009355275,0.00010550225,0.0001077534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007886402,0.0003233887,0.00068610243,0.000071489485,0.00050143135,0.00013343581,0.00031306557,0.000084808846,0.00012134435],"category_scores_gemma":[0.0007944678,0.00017852118,0.00023730125,0.0003964176,0.00026956314,0.00008871702,0.00006494302,0.000436961,0.000035356898],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28057402,0.009696161,0.1307592,0.00008067227,0.003476125,0.0008996917,0.0080185095,0.00010340686,0.0003008669,0.0035796023,0.53407604,0.028435702],"study_design_scores_gemma":[0.6403892,0.000864359,0.13687746,0.00097593677,0.0009103691,0.000012568573,0.0032134356,0.00015887793,0.002278015,0.0007603972,0.21312256,0.00043684064],"about_ca_topic_score_codex":0.0077588963,"about_ca_topic_score_gemma":0.004095236,"teacher_disagreement_score":0.35981515,"about_ca_system_score_codex":0.0007119823,"about_ca_system_score_gemma":0.0006799317,"threshold_uncertainty_score":0.9988485},"labels":[],"label_agreement":null},{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","score_opus":0.020862588265296064,"score_gpt":0.3186337084991464,"score_spread":0.29777112023385033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923073,0.003454718,0.0001618804,0.00041918203,0.0002789595,0.0026199226,0.0002563859,0.000048503287,0.00045311838],"genre_scores_gemma":[0.9962707,0.002144868,0.00024289379,0.00007572161,0.00006874132,0.00023010254,0.00046545573,0.000041156803,0.0004603279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972021,0.00016551315,0.0009092599,0.0006014639,0.0005316135,0.0005900539],"domain_scores_gemma":[0.99826777,0.00037477366,0.00028173733,0.0006653774,0.00018912113,0.00022124781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030384213,0.00036926905,0.0012564593,0.00054361246,0.00009838916,0.000016294907,0.00023366322,0.0001940184,0.00028782338],"category_scores_gemma":[0.00049889873,0.00034097725,0.0001951836,0.0008102265,0.0003451445,0.00013814955,0.00016473343,0.00042373192,0.000003887915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3631703,0.005538309,0.49363843,0.0026923865,0.0030989298,0.0013143682,0.0009471375,0.00015132099,0.024985597,0.00043146173,0.0007882977,0.103243485],"study_design_scores_gemma":[0.46504638,0.005032033,0.50306463,0.0021554634,0.00043863716,0.000025008709,0.00029379575,0.0033505755,0.01866685,0.00026739726,0.0012675071,0.00039168974],"about_ca_topic_score_codex":0.009569853,"about_ca_topic_score_gemma":0.00587643,"teacher_disagreement_score":0.10285179,"about_ca_system_score_codex":0.00081694004,"about_ca_system_score_gemma":0.00071328133,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W4417530897","doi":"10.1016/j.esmorc.2025.100090","title":"CIRCULATING TUMOR DNA IN PATIENTS WITH INTERMEDIATE RISK RHABDOMYOSARCOMA ON ARST1431: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"School of Medicine, Duke University; Università degli Studi di Padova; Centre Léon Bérard; Ohio State University; Institut Gustave-Roussy; Nationwide Children's Hospital","keywords":"Circulating tumor DNA; Rhabdomyosarcoma; Mutation; Retrospective cohort study; Disease; Circulating tumor cell; Cancer","score_opus":0.003196162349068001,"score_gpt":0.21687995049723713,"score_spread":0.21368378814816913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970235,0.00038921533,0.00017951017,0.00029126677,0.00048494787,0.0004067122,0.00021704669,0.00001047583,0.0009972764],"genre_scores_gemma":[0.99604756,0.00010961999,0.00012872662,0.0027350902,0.00026282313,0.00007832877,0.0005854002,0.00002290372,0.000029529127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987386,0.00007688904,0.0002924792,0.0005030362,0.00012083691,0.0002681854],"domain_scores_gemma":[0.9990071,0.00011605615,0.00022671137,0.0005379404,0.00005926583,0.00005289919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014021735,0.00019456346,0.000220387,0.000046599347,0.00010279799,0.000028677248,0.00026043394,0.0001082272,0.00001550947],"category_scores_gemma":[0.0002871805,0.00015010197,0.00007166292,0.00014365093,0.00011314651,0.000003594309,0.00014626073,0.00024449066,0.0000028083202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000584444,0.000106787775,0.9750984,0.000005357081,0.00015981494,0.00009563455,0.000116898605,0.00043696148,0.00027004164,0.000041422038,0.0064804573,0.016603798],"study_design_scores_gemma":[0.0024274066,0.00046852947,0.9777695,0.00009856411,0.0000467113,0.0000063683183,0.00006987214,0.000036796933,0.0011992702,0.00014824409,0.01751612,0.00021262477],"about_ca_topic_score_codex":0.002392098,"about_ca_topic_score_gemma":0.004190274,"teacher_disagreement_score":0.016391173,"about_ca_system_score_codex":0.0002812495,"about_ca_system_score_gemma":0.00040958522,"threshold_uncertainty_score":0.6120981},"labels":[],"label_agreement":null},{"id":"W4417530898","doi":"10.1016/j.esmorc.2025.100059","title":"DISSECTING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC TARGETS FROM SINGLE-NUCLEI RNA-SEQ OF CIC::DUX4 ROUND CELL SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Sarcoma; Cell; Tumor cells; Clear-cell sarcoma; Chemotherapy; Cell culture","score_opus":0.023830504558283866,"score_gpt":0.2642154732002451,"score_spread":0.2403849686419612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95119274,0.044793617,0.000083658044,0.00035750464,0.00046383313,0.0004451719,0.00012491822,0.00005782735,0.0024807344],"genre_scores_gemma":[0.99742335,0.0008402677,0.00057038525,0.0005997478,0.00010022261,0.000048528527,0.00005705158,0.000041697698,0.00031873208],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984276,0.000056232362,0.00039269208,0.0005306572,0.00023563657,0.00035714157],"domain_scores_gemma":[0.99885154,0.00025167348,0.00018275926,0.00044615916,0.00012156457,0.00014628765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000086011976,0.00029837684,0.00054885383,0.00011383868,0.00013346702,0.00004690768,0.000120133875,0.00007656359,0.00017320212],"category_scores_gemma":[0.000015333939,0.00025848422,0.00015238055,0.00022450832,0.000101216145,0.000083524574,0.00007586076,0.00019130613,0.000008739443],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010938043,0.002218672,0.81670976,0.00061881,0.00082955894,0.0006600385,0.002244484,0.0000749152,0.09460497,0.00007086426,0.003046274,0.07782784],"study_design_scores_gemma":[0.0045103324,0.00039373717,0.25419447,0.0003465163,0.0003085562,0.0000083002715,0.0010749968,0.00013337503,0.7270891,0.0004966314,0.011119041,0.00032492532],"about_ca_topic_score_codex":0.0012170529,"about_ca_topic_score_gemma":0.00037301253,"teacher_disagreement_score":0.63248414,"about_ca_system_score_codex":0.0005928317,"about_ca_system_score_gemma":0.00013441166,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4417530903","doi":"10.1016/j.esmorc.2025.100079","title":"PREOPERATIVE RADIOTHERAPY AND POSTOPERATIVE COMPLICATIONS AMONG PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA: A POST HOC ANALYSIS OF THE EORTC-62092 (STRASS) PHASE 3 RANDOMIZED CLINICAL TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; Post-hoc analysis; Clinical trial; Radiation therapy; Intention-to-treat analysis; Post hoc","score_opus":0.01606725772035284,"score_gpt":0.33226002791445214,"score_spread":0.3161927701940993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089175,0.0016708752,0.00009542761,0.0024913077,0.0001535208,0.0035854147,0.00025243912,0.000021472848,0.0008377814],"genre_scores_gemma":[0.9960921,0.0004301831,0.00056382123,0.0019347409,0.000039033544,0.00050512684,0.000286495,0.000016223781,0.00013227193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978618,0.0005440557,0.0006781554,0.00045363943,0.00028266793,0.00017968245],"domain_scores_gemma":[0.9979839,0.000707004,0.00028022483,0.0005009084,0.00042133185,0.00010664556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032756315,0.00024150466,0.0013568868,0.00017719512,0.00019230928,0.000032141666,0.00012836562,0.00010166528,0.00006969149],"category_scores_gemma":[0.0001850501,0.00013243123,0.0004317163,0.0007562423,0.0008060824,0.00008830408,0.00004273597,0.0002283099,3.7398559e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34068778,0.0020378735,0.63736254,0.000019316942,0.0089135,0.000008338375,0.00076902984,0.000020490628,0.000018720777,0.00018881938,0.0005758151,0.009397763],"study_design_scores_gemma":[0.39484248,0.0011209934,0.6002001,0.00010573626,0.0029936375,7.9079956e-7,0.00010054518,0.00023066957,0.000089134795,0.000003067289,0.00022229525,0.00009052698],"about_ca_topic_score_codex":0.00050493464,"about_ca_topic_score_gemma":0.0003299517,"teacher_disagreement_score":0.054154694,"about_ca_system_score_codex":0.0003863765,"about_ca_system_score_gemma":0.0005539578,"threshold_uncertainty_score":0.5400389},"labels":[],"label_agreement":null},{"id":"W4417530910","doi":"10.1016/j.esmorc.2025.100062","title":"MINNELIDE IS A NOVEL THERAPEUTIC INHIBITOR OF CIC::DUX4 SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Magnesium in Health and Disease","field":"Nursing","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sarcoma; Cancer; Immunotherapy; Soft tissue sarcoma; Drug","score_opus":0.019101758309346035,"score_gpt":0.3049709616630899,"score_spread":0.2858692033537439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8695884,0.025983054,0.00083934,0.041966714,0.011092194,0.0018513759,0.00055337825,0.00037480443,0.04775078],"genre_scores_gemma":[0.98266846,0.000012994544,0.0002599631,0.015675776,0.0002576568,0.0000567407,0.000012139764,0.000020385014,0.0010359127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986771,0.000043243235,0.00036368065,0.00032217495,0.00021343613,0.00038037225],"domain_scores_gemma":[0.99903375,0.00012525727,0.00012040057,0.00043028218,0.00012669303,0.00016361118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000108844164,0.00017730868,0.00026814057,0.00015157503,0.000118313445,0.00002016499,0.00021566679,0.00011410183,0.00076086744],"category_scores_gemma":[0.000088091605,0.00017381091,0.00011894114,0.000427233,0.00010401538,0.00008682597,0.000038956114,0.0001564655,0.00002101538],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009123942,0.001096464,0.14027472,0.012569277,0.00019953282,0.00004403628,0.007276993,0.00012314106,0.024517238,0.006813947,0.40745795,0.39050275],"study_design_scores_gemma":[0.011693559,0.00094355526,0.15631136,0.0010224992,0.0006648031,0.000012130281,0.00206059,0.002691833,0.21258648,0.007825093,0.6028058,0.0013822713],"about_ca_topic_score_codex":0.0013482443,"about_ca_topic_score_gemma":0.000114497,"teacher_disagreement_score":0.3891205,"about_ca_system_score_codex":0.00026856866,"about_ca_system_score_gemma":0.00045705153,"threshold_uncertainty_score":0.83309644},"labels":[],"label_agreement":null},{"id":"W7116631298","doi":"10.1016/j.esmorc.2025.100103","title":"PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fibrosis; Soft tissue sarcoma; Soft tissue; Thigh; Sarcoma; Subcutaneous tissue; Vortex","score_opus":0.04187978627994771,"score_gpt":0.3401438212695845,"score_spread":0.2982640349896368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116631298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716659,0.01898696,0.00049573963,0.004335823,0.000671868,0.002709419,0.00026102317,0.00009932789,0.0007739102],"genre_scores_gemma":[0.99557054,0.00045115288,0.0020078365,0.0007294267,0.00029164946,0.00030927642,0.000040445597,0.000030375599,0.00056926865],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843955,0.00011599397,0.0004927256,0.00042021286,0.00017934105,0.00035217078],"domain_scores_gemma":[0.9979792,0.0012625619,0.00019049847,0.00034754028,0.00010842528,0.000111738875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004267318,0.00024631224,0.00065841957,0.0000973742,0.00029670546,0.000062234336,0.00010266661,0.00013868208,0.0001583964],"category_scores_gemma":[0.0005208803,0.00017408354,0.00018730297,0.00018431002,0.00023718561,0.000057822836,0.00006683341,0.00014787524,0.0000026653115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058430308,0.00047602254,0.3363367,0.0009551413,0.0024583966,0.00079736306,0.0020910257,0.00014838208,0.0048997803,0.0004826219,0.022772154,0.6227394],"study_design_scores_gemma":[0.04307815,0.012249577,0.6525518,0.0088944305,0.016755085,0.0044666696,0.0114109665,0.019559024,0.0799652,0.0027239912,0.14619048,0.0021546346],"about_ca_topic_score_codex":0.0004989105,"about_ca_topic_score_gemma":0.00003748196,"teacher_disagreement_score":0.6205847,"about_ca_system_score_codex":0.00036888188,"about_ca_system_score_gemma":0.00037586744,"threshold_uncertainty_score":0.7098921},"labels":[],"label_agreement":null},{"id":"W7116631937","doi":"10.1016/j.esmorc.2025.100070","title":"EXPLORING ACTIONABLE THERAPEUTIC TARGETS ASSOCIATED WITH SMARCB1 DEFICIENCY IN EPITHELIOID SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epithelioid sarcoma; Sarcoma; SMARCB1; Disease; Mutation; Soft tissue sarcoma","score_opus":0.03014984236719089,"score_gpt":0.2573838991908916,"score_spread":0.2272340568237007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116631937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870236,0.0055583166,0.0013362956,0.00026100408,0.00027992792,0.00015889882,0.000012439144,0.000032597556,0.0053369147],"genre_scores_gemma":[0.99746764,0.0005759239,0.00011723847,0.00043800785,0.000055544606,0.00011274017,0.0000520081,0.000017703054,0.0011631959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990999,0.000041366937,0.00015256385,0.0003169191,0.000113582486,0.00027562884],"domain_scores_gemma":[0.9996009,0.000016181737,0.000053629596,0.0002288101,0.00006761602,0.00003284589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012522966,0.00013969926,0.00013972571,0.00007233509,0.00009434142,0.000018426974,0.00014411131,0.00008019374,0.000034899622],"category_scores_gemma":[0.000036427096,0.0001264879,0.000047314177,0.00028582162,0.0000482378,0.000009284859,0.000037764807,0.00012331763,0.0000025718903],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022700608,0.0009325102,0.16904698,0.00058381975,0.0012764301,0.000102857055,0.0027677647,0.10273181,0.47918072,0.0019874861,0.0156008145,0.22351871],"study_design_scores_gemma":[0.010207556,0.0011983825,0.19941,0.001578722,0.00018836977,0.000026484275,0.003345033,0.006479945,0.6427519,0.001719255,0.13087904,0.002215347],"about_ca_topic_score_codex":0.00024974902,"about_ca_topic_score_gemma":0.00087666477,"teacher_disagreement_score":0.22130337,"about_ca_system_score_codex":0.00024272446,"about_ca_system_score_gemma":0.00037337383,"threshold_uncertainty_score":0.5158027},"labels":[],"label_agreement":null}]}